BRPI0811476A2 - Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível - Google Patents

Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível

Info

Publication number
BRPI0811476A2
BRPI0811476A2 BRPI0811476-5A2A BRPI0811476A BRPI0811476A2 BR PI0811476 A2 BRPI0811476 A2 BR PI0811476A2 BR PI0811476 A BRPI0811476 A BR PI0811476A BR PI0811476 A2 BRPI0811476 A2 BR PI0811476A2
Authority
BR
Brazil
Prior art keywords
reversible
intravenous
inhibitor
direct
oral dosage
Prior art date
Application number
BRPI0811476-5A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert M Scarborough
Daniel D Gretler
Pamela B Conley
Patrick Andre
Athiwat Hutchaleelaha
David R Philips
Anjali Pandey
Huang Wolin
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of BRPI0811476A2 publication Critical patent/BRPI0811476A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0811476-5A2A 2007-05-02 2008-05-02 Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível BRPI0811476A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
BRPI0811476A2 true BRPI0811476A2 (pt) 2014-11-04

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811476-5A2A BRPI0811476A2 (pt) 2007-05-02 2008-05-02 Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível

Country Status (17)

Country Link
US (2) US20090048216A1 (enExample)
EP (1) EP2079464A2 (enExample)
JP (1) JP2010526101A (enExample)
KR (1) KR20100029746A (enExample)
CN (1) CN101795682A (enExample)
AU (1) AU2008247483A1 (enExample)
BR (1) BRPI0811476A2 (enExample)
CA (1) CA2686203A1 (enExample)
CO (1) CO6241104A2 (enExample)
EA (1) EA200901473A1 (enExample)
EC (1) ECSP099778A (enExample)
GT (1) GT200900284A (enExample)
IL (1) IL201834A0 (enExample)
MA (1) MA31663B1 (enExample)
MX (1) MX2009011843A (enExample)
TN (1) TN2009000451A1 (enExample)
WO (1) WO2008137753A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006311795B2 (en) * 2005-11-03 2013-01-17 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
MX2009009492A (es) * 2007-03-06 2009-09-15 Novartis Ag Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
KR20100020455A (ko) * 2007-05-02 2010-02-22 포톨라 파마슈티컬스, 인코포레이티드 상이한 결정질 형태의 [4-(6-플루오로-7-메틸아미노-2,4-디옥소-1,4-디히드로-2ｈ-퀴나졸린-3-일)-페닐]-5-클로로-티오펜-2-일-술포닐우레아염, 및 이의 제약 조성물
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2384196B1 (en) * 2008-12-30 2017-09-13 Johansson, Pär Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
SI2498731T1 (sl) 2009-11-11 2020-05-29 Chiesi Farmaceutici S.P.A. Postopki zdravljenja ali preprečevanja tromboze stenta
EP2515871B1 (en) * 2009-12-23 2015-09-23 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2012072743A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
WO2012072824A1 (en) * 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
UA125531C2 (uk) 2017-03-15 2022-04-13 Ідорсія Фармасьютікалз Лтд ПІДШКІРНЕ ВВЕДЕННЯ АНТАГОНІСТА P2Y<sub>12</sub> РЕЦЕПТОРА
EP3641784A1 (en) 2017-06-23 2020-04-29 Chiesi Farmaceutici S.p.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
AU2006311795B2 (en) 2005-11-03 2013-01-17 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Also Published As

Publication number Publication date
JP2010526101A (ja) 2010-07-29
CO6241104A2 (es) 2011-01-20
MX2009011843A (es) 2010-04-22
US20090048216A1 (en) 2009-02-19
WO2008137753A3 (en) 2009-02-12
GT200900284A (es) 2012-01-31
AU2008247483A1 (en) 2008-11-13
MA31663B1 (fr) 2010-09-01
CN101795682A (zh) 2010-08-04
ECSP099778A (es) 2010-01-29
WO2008137753A2 (en) 2008-11-13
CA2686203A1 (en) 2008-11-13
IL201834A0 (en) 2010-06-16
TN2009000451A1 (en) 2011-03-31
US20120009172A1 (en) 2012-01-12
KR20100029746A (ko) 2010-03-17
EP2079464A2 (en) 2009-07-22
EA200901473A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
BRPI0811476A2 (pt) Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível
KR101710881B9 (ko) Ｄｐｐ ｉｖ 억제제 제형
EP2047820A4 (en) ORTHODONTIC FASTENING BRIDGE
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
BRPI0918360A2 (pt) composto, composição farmacêutica e usos de um composto
KR101522157B9 (ko) Ｃｏｍｔ 억제제의 투약 방법
EP2132133A4 (en) RELEASE OF PARTICULATE ACTIVE SUBSTANCES
DK2399579T3 (da) Farmaceutiske doseringsformer
EP2147437A4 (en) SEEDING REPLICATION
EP2320893A4 (en) COMBINATION OF A TRIPTAN AND AN NSAR
PT2397142T (pt) Utilizações de inibidores da dpp iv
DK2077729T3 (da) Orale probiotiske doseringsformer
BRPI0716365A2 (pt) &#34;artigo odontolàgico&#34;
GB0703438D0 (en) Preventing spread of infection
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
HRP20192282T8 (hr) Inhibitori tfpi i postupci upotrebe
EP2185112A4 (en) Stabilized therapeutic compositions and formulations
DE602007010119D1 (de) Mundpflegezusammensetzung mit silikonverbund
BRPI0810581A2 (pt) Produto refratário fundido e moldado e utilização de um produto
IL202765A0 (en) Pharmaceutical combination of nsaid and prostaglandin compound
DE602008005137D1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
PT2271348T (pt) Formulação de comprimido oral de composto de tetraciclina
NO20083139L (no) Anvendelse av hyllebærekstrakt

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]